154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer
| Autor: | Fasching, P.A., Clifton, K., Katashvili, Z., Nemsadze, G., Makharadze, T., Arkania, E., Gogishvili, M., Lachowicz, M., Gedrich, R., Ranciato, J., Zhi, E., Perkins, J., Jañez, N. Martinez, Hurvitz, S.A. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|